Literature DB >> 29763890

MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.

Sandra Lettlova1,2, Veronika Brynychova3,4, Jan Blecha1, David Vrana3,5, Magdalena Vondrusova1, Pavel Soucek3,4, Jaroslav Truksa1.   

Abstract

BACKGROUND/AIMS: MiRNA-301a-3p is an oncogenic miRNA whose expression is associated with tumor development, metastases and overall poor prognosis. Estrogen receptor α (ERα) is one of the estrogen hormone-activated transcription factors, which regulates a large number of genes and is involved in the mammary gland development. Expression of ERα is considered to be a good indicator for endocrine therapy and breast cancer survival. Loss of ERα in breast cancer patients indicates invasiveness and poor prognosis. In this study, we focus on the regulation of ERα by miR-301a and its role in transition from estrogen-dependent to estrogen-independent breast cancer.
METHODS: Expression of miR-301a-3p was measured by qRT-PCR in tumor tissue samples from 111 patients with primary breast carcinoma and in mammospheres representing in vitro model of cancer stem-like cells. Dual reporter luciferase assay and complementary experiments were performed to validate ESR1 as a direct target of miR-301a-3p. The effect of miR-301a-3p on estrogen signaling was evaluated on the level of gene and protein expression and growth response to estrogens. Finally, the effect of miR-301a-3p expression on tumor growth was studied in nude mice.
RESULTS: We identified ESR1 as a direct target of miR-301a-3p. Ectopic miR-301a-3p causes a decrease in ESR1 mRNA and protein level and modulates the expression of ERα target genes in ERα positive breast cancer cells. Consistently, miR-301a-3p causes a decrease in sensitivity of MCF7 cells to 17β-estradiol and inhibits the growth of estrogen dependent tumor in nude mice. Yet, the mice tumors have significantly increased expression of genes related to cancer stem-like cells and epithelial to mesenchymal transition suggesting enrichment of the population of cells with more invasive properties, in line with our observation that miR-301a-3p expression is highly increased in mammospheres which show a decrease in estrogenic signaling. Importantly, miR-301a-3P level is also increased in primary breast cancer samples exhibiting an ER/PR negative phenotype.
CONCLUSION: Our results confirm ESR1 as a direct target of miR-301a-3p and suggest that miR-301a-3p likely contributes to development of estrogen independence, which leads to a more invasive phenotype of breast cancer.
© 2018 The Author(s). Published by S. Karger AG, Basel.

Entities:  

Keywords:  Breast cancer; ERα; Estrogen dependence; Estrogen signaling; MiR-301a

Mesh:

Substances:

Year:  2018        PMID: 29763890     DOI: 10.1159/000489687

Source DB:  PubMed          Journal:  Cell Physiol Biochem        ISSN: 1015-8987


  11 in total

1.  miRNA profile obtained by next‑generation sequencing in metastatic breast cancer patients is able to predict the response to systemic treatments.

Authors:  Antonio Daniel Martinez-Gutierrez; Oliver Millan Catalan; Rafael Vázquez-Romo; Fany Iris Porras Reyes; Alberto Alvarado-Miranda; Fernando Lara Medina; Juan E Bargallo-Rocha; Luz Tonatzin Orozco Moreno; David Cantú De León; Luis Alonso Herrera; César López-Camarillo; Carlos Pérez-Plasencia; Alma D Campos-Parra
Journal:  Int J Mol Med       Date:  2019-07-30       Impact factor: 4.101

2.  Exosomes derived from miR-301a-3p-overexpressing adipose-derived mesenchymal stem cells reverse hypoxia-induced erectile dysfunction in rat models.

Authors:  Li Liang; Dachao Zheng; Chao Lu; Qinghong Xi; Hua Bao; Wengfeng Li; Yufei Gu; Yuanshen Mao; Bin Xu; Xin Gu
Journal:  Stem Cell Res Ther       Date:  2021-01-25       Impact factor: 6.832

3.  Exosomal microRNA-301a-3p promotes the proliferation and invasion of nasopharyngeal carcinoma cells by targeting BTG1 mRNA.

Authors:  Qiang Cheng; Qiang Li; Lingen Xu; Hui Jiang
Journal:  Mol Med Rep       Date:  2021-03-24       Impact factor: 2.952

Review 4.  Preclinical Imaging Evaluation of miRNAs' Delivery and Effects in Breast Cancer Mouse Models: A Systematic Review.

Authors:  Francesca Maria Orlandella; Luigi Auletta; Adelaide Greco; Antonella Zannetti; Giuliana Salvatore
Journal:  Cancers (Basel)       Date:  2021-11-30       Impact factor: 6.639

Review 5.  The role of exosomal microRNAs; focus on clinical applications in breast cancer.

Authors:  Aiko Sueta; Yutaka Yamamoto; Hirotaka Iwase
Journal:  Cancer Drug Resist       Date:  2019-09-19

6.  β-elemene suppresses Warburg effect in NCI-H1650 non-small-cell lung cancer cells by regulating the miR-301a-3p/AMPKα axis.

Authors:  Lin Li; Dongkai Zhao; Guangyu Cheng; Qingjie Li; Yunjie Chu; Hongbo Chu; Yunlu Ding; Chikun Li
Journal:  Biosci Rep       Date:  2020-06-26       Impact factor: 3.840

7.  Highly Variable Expression of ESR1 Splice Variants in Human Liver: Implication in the Liver Gene Expression Regulation and Inter-Person Variability in Drug Metabolism and Liver Related Diseases.

Authors:  J W Sun; J M Collins; D Ling; D Wang
Journal:  J Mol Genet Med       Date:  2019-09-30

8.  Specific microRNA signatures in exosomes of triple-negative and HER2-positive breast cancer patients undergoing neoadjuvant therapy within the GeparSixto trial.

Authors:  Ines Stevic; Volkmar Müller; Karsten Weber; Peter A Fasching; Thomas Karn; Frederic Marmé; Christian Schem; Elmar Stickeler; Carsten Denkert; Marion van Mackelenbergh; Christoph Salat; Andreas Schneeweiss; Klaus Pantel; Sibylle Loibl; Michael Untch; Heidi Schwarzenbach
Journal:  BMC Med       Date:  2018-10-10       Impact factor: 8.775

9.  Five miRNAs-mediated PIEZO2 downregulation, accompanied with activation of Hedgehog signaling pathway, predicts poor prognosis of breast cancer.

Authors:  Weiyang Lou; Jingxing Liu; Bisha Ding; Luqi Jin; Liang Xu; Xia Li; Jing Chen; Weimin Fan
Journal:  Aging (Albany NY)       Date:  2019-05-06       Impact factor: 5.682

10.  MiR-130a-3p Inhibits PRL Expression and Is Associated With Heat Stress-Induced PRL Reduction.

Authors:  Haojie Zhang; Ting Chen; Jiali Xiong; Baoyu Hu; Junyi Luo; Qianyun Xi; Qingyang Jiang; Jiajie Sun; Yongliang Zhang
Journal:  Front Endocrinol (Lausanne)       Date:  2020-03-03       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.